DiaSorin (OTCMKTS:DSRLF) Shares Gap Down – What’s Next?

Shares of DiaSorin S.p.A. (OTCMKTS:DSRLF) gapped down before the market opened on Thursday . The stock had previously closed at $78.45, but opened at $74.25. DiaSorin shares last traded at $74.25, with a volume of 10 shares trading hands.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on DSRLF shares. Deutsche Bank Aktiengesellschaft lowered shares of DiaSorin from a “hold” rating to a “sell” rating in a research note on Wednesday. UBS Group downgraded shares of DiaSorin from a “buy” rating to a “neutral” rating in a research note on Thursday, April 9th. Zacks Research raised DiaSorin to a “hold” rating in a research report on Tuesday, May 12th. Finally, Piper Sandler assumed coverage on DiaSorin in a research report on Thursday, June 11th. They issued a “neutral” rating for the company. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold”.

DiaSorin Stock Performance

The business’s 50 day simple moving average is $72.55 and its 200-day simple moving average is $75.54.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italy?based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over?the?counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.